Turmeric-Based drug tested in Hard-to-Treat blood cancer

NCT ID NCT07456605

Recruiting now Disease control Sponsor: University Health Network, Toronto Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase study tests a new form of curcumin (the active ingredient in turmeric) that is wrapped in tiny fat particles to help the body absorb it better. The goal is to find the safest dose for people with multiple myeloma that has come back or stopped responding to standard treatments. Twenty participants will receive increasing doses to monitor side effects and see if the drug can control the cancer.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: liposomal curcumin
What this could lead to: If it works, this could point toward a new treatment option for multiple myeloma that has stopped responding to other therapies.
What could go wrong: This is a very early Phase 1 trial with only 20 people, focused on safety and dosing. It may not show any anti-cancer effect, and side effects could be severe.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA IN RELAPSE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma refractory plasma cell neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE MYELOMA IN RELAPSE MULTIPLE MYELOMA REFRACTORY

Contacts and locations

Locations

University Health Network-Princess Margaret Cancer Centre
RECRUITING

Toronto, Ontario, M5G 2M9, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.